Stockscreener 앱 받기
14.92
3.70%
0.595
전일 마감가:
$14.32
열려 있는:
$14.62
하루 거래량:
52,690
Relative Volume:
0.90
시가총액:
$104.33M
수익:
$100.44M
순이익/손실:
$-133.16M
주가수익비율:
-0.5792
EPS:
-25.76
순현금흐름:
$-94.85M
1주 성능:
+6.26%
1개월 성능:
+22.57%
6개월 성능:
+168.63%
1년 성능:
+84.99%
1일 변동 폭
$14.30
$15.35
1주일 범위
$13.89
$16.72
52주 변동 폭
$5.005
$18.70
아타라 Stock (ATRA) Company Profile
명칭
Atara Biotherapeutics Inc
전화
805-623-4211
주소
1280 RANCHO CONEJO BLVD, THOUSAND OAKS, CA
ATRA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ATRA
Atara Biotherapeutics Inc
|
14.86 | 100.60M | 100.44M | -133.16M | -94.85M | -25.76 |
|
VRTX
Vertex Pharmaceuticals Inc
|
408.60 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
472.79 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.54 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
801.70 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
331.41 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
아타라 Stock (ATRA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-11-09 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2023-11-09 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2023-11-09 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2022-07-20 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2022-07-13 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2022-07-13 | 다운그레이드 | Stifel | Buy → Hold |
| 2022-05-10 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2021-05-13 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2020-12-09 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-12-08 | 재확인 | H.C. Wainwright | Buy |
| 2020-11-10 | 재확인 | H.C. Wainwright | Buy |
| 2020-06-30 | 개시 | Evercore ISI | Outperform |
| 2020-06-15 | 개시 | H.C. Wainwright | Buy |
| 2020-04-23 | 업그레이드 | Citigroup | Neutral → Buy |
| 2019-11-08 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2019-09-27 | 다운그레이드 | Goldman | Neutral → Sell |
| 2019-09-16 | 다운그레이드 | Jefferies | Buy → Hold |
| 2019-06-04 | 업그레이드 | Citigroup | Sell → Neutral |
| 2019-05-30 | 개시 | ROTH Capital | Buy |
| 2019-05-23 | 개시 | Stifel | Buy |
| 2019-01-23 | 개시 | Mizuho | Buy |
| 2018-04-10 | 개시 | JP Morgan | Overweight |
| 2018-03-16 | 개시 | Guggenheim | Neutral |
| 2018-03-05 | 재확인 | Jefferies | Buy |
| 2018-02-28 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2018-02-15 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2018-01-03 | 업그레이드 | Citigroup | Sell → Neutral |
| 2017-10-06 | 재개 | Goldman | Neutral |
모두보기
아타라 주식(ATRA)의 최신 뉴스
How Atara Biotherapeutics Inc. stock reacts to global recession fearsJuly 2025 Opening Moves & Safe Entry Point Alerts - newser.com
How to use Fibonacci retracement on Atara Biotherapeutics Inc.Buy Signal & Fast Gain Swing Alerts - newser.com
Will Atara Biotherapeutics Inc. stock maintain growth storyMarket Risk Analysis & Consistent Return Strategy Ideas - newser.com
Volume spikes in Atara Biotherapeutics Inc. stock – what they meanMarket Sentiment Review & Weekly Hot Stock Watchlists - newser.com
Can you recover from losses in Atara Biotherapeutics Inc.July 2025 Movers & Comprehensive Market Scan Insights - newser.com
Chart based exit strategy for Atara Biotherapeutics Inc.Market Activity Summary & Safe Investment Capital Preservation Plans - newser.com
Using economic indicators to assess Atara Biotherapeutics Inc. potentialJuly 2025 Selloffs & AI Forecast for Swing Trade Picks - newser.com
Will Atara Biotherapeutics Inc. continue its uptrendWeekly Risk Summary & Precise Buy Zone Tips - newser.com
What hedge fund activity signals for Atara Biotherapeutics Inc. stockJuly 2025 Volume & Capital Efficient Trading Techniques - newser.com
How rising interest rates impact Atara Biotherapeutics Inc. stockRisk Management & Free Technical Confirmation Trade Alerts - newser.com
Atara Biotherapeutics' (ATRA) "Sell (D+)" Rating Reaffirmed at Weiss Ratings - MarketBeat
Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Stock Catapults 30% Though Its Price And Business Still Lag The Industry - simplywall.st
Atara Biotherapeutics Inc. stock trendline breakdownQuarterly Profit Report & Comprehensive Market Scan Insights - newser.com
Statistical indicators supporting Atara Biotherapeutics Inc.’s strengthJuly 2025 Rallies & Verified Momentum Stock Ideas - newser.com
Pattern recognition hints at Atara Biotherapeutics Inc. upside2025 Momentum Check & Reliable Entry Point Trade Alerts - newser.com
Atara Biotherapeutics Inc Stock Analysis and ForecastAutomated Trading Signals & Your Free Entry to Smart Investing Starts Here - earlytimes.in
Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Receives $21.00 Consensus Price Target from Brokerages - Defense World
How Atara Biotherapeutics Inc. (AT20) stock stacks up against competitorsNew Guidance & Real-Time Market Trend Scan - newser.com
Is Atara Biotherapeutics Inc. stock positioned for long term growthPortfolio Value Report & Expert Verified Stock Movement Alerts - newser.com
What drives Atara Biotherapeutics Inc stock priceStock Price Divergence & Low Entry Capital Stocks - earlytimes.in
Can swing trading help recover from Atara Biotherapeutics Inc. losses2025 Top Decliners & Technical Entry and Exit Alerts - newser.com
Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Pancreatic Cancer Market Positioned for Accelerated Development Through 2034, DelveInsight Finds | Dragonfly Therapeutics, Keymed B, Tango Therapeutics, Atara Bio, Keymed Biosciences, Carisma Therapeu - Barchart.com
While institutions own 28% of Atara Biotherapeutics, Inc. (NASDAQ:ATRA), individual investors are its largest shareholders with 35% ownership - Yahoo Finance
Cancer stocks rebound, outpacing broader markets in Q3 2025 - BioWorld MedTech
Analyzing net buyer seller activity in Atara Biotherapeutics Inc.Quarterly Investment Review & Reliable Volume Spike Alerts - newser.com
4 Biotechnology Stocks That Outshine In Momentum Amid Strong Technicals - inkl
Atara Biotherapeutics (ATRA) Reports Q4 Loss, Tops Revenue Estimates - MSN
아타라 (ATRA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
아타라 주식 (ATRA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Grant-Huerta Yanina | Chief Accounting Officer |
Aug 18 '25 |
Sale |
11.61 |
1,809 |
21,009 |
35,258 |
| Panacea Innovation Ltd | 10% Owner |
Aug 15 '25 |
Buy |
12.19 |
55,000 |
670,422 |
1,405,000 |
1.24%
자본화:
|
볼륨(24시간):